Article    Table of Contents                    Full Text of this article Free    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search                            Get Permissions  Google Scholar    Search for Related Content  PubMed Articles in PubMed by Author:    Kozal, M. J.    Merigan, T. C.    Related Articles in PubMed    PubMed Citation    PubMed

ARTICLE

Didanosine Resistance in HIV-infected Patients Switched from Zidovudine to Didanosine Monotherapy

Michael J. Kozal; Kenda Kroodsma; Mark A. Winters; Robert W. Shafer; Brad Efron; David A. Katzenstein; and Thomas C. Merigan

15 August 1994 | Volume 121 Issue 4 | Pages 263-268

Objective: To determine the frequency and pattern of development of specific drug resistance mutations for human immunodeficiency virus (HIV) reverse transcriptase in patients switched from zidovudine to didanosine therapy and to examine the relation of the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene to CD4⁺ T-cell changes and virus burden.

Design: Retrospective analysis of all patients enrolled at Stanford University in protocols where patients were switched from zidovudine to didanosine monotherapy.

Setting: A university hospital.

Patients: 64 patients infected with HIV who were switched from zidovudine to didanosine monotherapy. Patients had the acquired immunodeficiency syndrome (AIDS), AIDS-related complex, or were asymptomatic (mean [±SD] starting CD4⁺ T-cell count of 129 ±88 cells/mm³).

Measurements: Serial serum specimens were tested for the didanosine resistance mutation at codon 74 of the HIV reverse-transcriptase gene and for a zidovudine resistance mutation at codon 215 using selective polymerase chain reactions (PCR). Serum HIV RNA levels were determined by quantitative PCR. CD4⁺ T-cell counts were determined at serial time points.

Results: By 24 weeks of didanosine therapy, the proportion of patients with the didanosine resistance mutation at codon 74 increased from 0% to 56% (36 of 64). In contrast, the proportion of patients with the zidovudine resistance mutation at codon 215 decreased from 84% at the start to 59% after 24 weeks of didanosine therapy (a 25% decrease, 95% lower CI, 15%; P < 0.0001). Patients who developed the codon 74 mutation had a greater decrease in CD4⁺ T cells after the development of the mutation than did patients without the mutation (P < 0.001). In addition, after 24 weeks of didanosine, patients who developed the codon 74 mutation had a greater serum HIV RNA burden than patients who remained wild type (did not have the mutation) at codon 74 (225 000 compared with 82 400 HIV RNA copies/mL serum; P = 0.01).

Conclusions: Among patients infected with HIV who had advanced disease and were switched from zidovudine to didanosine therapy, more than one half developed the didanosine resistance mutation at codon 74 by 24 weeks of didanosine therapy. Patients who developed the codon 74 mutation had a greater decline in CD4⁺ T cells after the development of the mutation and had a greater serum virus burden than did patients without the codon 74 mutation.

Author and Article Information

From Stanford University Medical Center, Stanford, California.
Requests for Reprints: Michael J. Kozal, MD, Division of Infectious Diseases, Stanford University Medical Center, Room S-156, Stanford, CA 94305.
Grant Support: In part by the National Institute of Health grants AI-27762 and AI-27666.

This article has been cited by other articles:

				M. Wirden, B. Roquebert, A. Derache, A. Simon, C. Duvivier, J. Ghosn, S. Dominguez, V. Boutonnet, Z. Ait-Arkoub, C. Katlama, et al. Risk Factors for Selection of the L74I Reverse Transcriptase Mutation in Human Immunodeficiency Virus Type 1-Infected Patients. Antimicrob. Agents Chemother., July 1, 2006; 50(7): 2553 - 2556. [Abstract] [Full Text] [PDF]

				D. Turner, B. Brenner, and M. A. Wainberg Relationships among various nucleoside resistance-conferring mutations in the reverse transcriptase of HIV-1 J. Antimicrob. Chemother., January 1, 2004; 53(1): 53 - 57. [Abstract] [Full Text] [PDF]

				R. W. Shafer Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance Clin. Microbiol. Rev., April 1, 2002; 15(2): 247 - 277. [Abstract] [Full Text] [PDF]

				S. K. Powell, M. E. Gates, G. Langford, M.-L. Gu, C. Lockey, Z. Long, and E. Otto Antiretroviral Agents Inhibit Infection of Human Cells by Porcine Endogenous Retroviruses Antimicrob. Agents Chemother., December 1, 2000; 44(12): 3432 - 3433. [Abstract] [Full Text]

				A. R. Zolopa, R. W. Shafer, A. Warford, J. G. Montoya, P. Hsu, D. Katzenstein, T. C. Merigan, and B. Efron HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed Ann Intern Med, December 7, 1999; 131(11): 813 - 821. [Abstract] [Full Text] [PDF]

				P. Kosalaraksa, M. F. Kavlick, V. Maroun, R. Le, and H. Mitsuya Comparative Fitness of Multi-Dideoxynucleoside-Resistant Human Immunodeficiency Virus Type 1 (HIV-1) in an In Vitro Competitive HIV-1 Replication Assay J. Virol., July 1, 1999; 73(7): 5356 - 5363. [Abstract] [Full Text]

				M. D. Miller, P. D. Lamy, M. D. Fuller, A. S. Mulato, N. A. Margot, T. Cihlar, and J. M. Cherrington Human Immunodeficiency Virus Type 1 Reverse Transcriptase Expressing the K70E Mutation Exhibits a Decrease in Specific Activity and Processivity Mol. Pharmacol., August 1, 1998; 54(2): 291 - 297. [Abstract] [Full Text]

				A. S. Mulato, P. D. Lamy, M. D. Miller, W.-X. Li, K. E. Anton, N. S. Hellmann, and J. M. Cherrington Genotypic and Phenotypic Characterization of Human Immunodeficiency Virus Type 1 Variants Isolated from AIDS Patients after Prolonged Adefovir Dipivoxil Therapy Antimicrob. Agents Chemother., July 1, 1998; 42(7): 1620 - 1628. [Abstract] [Full Text]

				M. S. Hirsch, B. Conway, R. T. D'Aquila, V. A. Johnson, F. Brun-Vezinet, B. Clotet, L. M. Demeter, S. M. Hammer, D. M. Jacobsen, D. R. Kuritzkes, et al. Antiretroviral Drug Resistance Testing in Adults With HIV Infection: Implications for Clinical Management JAMA, June 24, 1998; 279(24): 1984 - 1991. [Abstract] [Full Text] [PDF]

				J. M. Adams, M. J. Shelton, R. G. Hewitt, T. H. Grasela, M. DeRemer, and G. D. Morse Relationship between Didanosine Exposure and Surrogate Marker Response in Human Immunodeficiency Virus-Infected Outpatients Antimicrob. Agents Chemother., April 1, 1998; 42(4): 821 - 826. [Abstract] [Full Text]

				Antiretroviral Drug Resistance: Clinical Significance and Implications for HIV Pathogenesis AIDS Clinical Care, August 1, 1995; 1995(801): 1 - 1. [Full Text]